1. Inicio
  2. Proyectos y Estudios
  3. ESTUDIO EN FASE II, MULTICÉNTRICO, ABIERTO Y DE VARIAS COHORTES PARA EVALUAR LA SEGURIDAD Y LA EFICACIA DEL CC-90011 EN COMBINACIÓN CON NIVOLUMAB EN SUJETOS CON CÁNCERES AVANZADOS.

ESTUDIO EN FASE II, MULTICÉNTRICO, ABIERTO Y DE VARIAS COHORTES PARA EVALUAR LA SEGURIDAD Y LA EFICACIA DEL CC-90011 EN COMBINACIÓN CON NIVOLUMAB EN SUJETOS CON CÁNCERES AVANZADOS.

Datos básicos

Código:
CC-90011-ST-002
Protocolo:
CC-90011-ST-002
EUDRACT:
2019-004194-95
NCT:
Centro:
HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
Dotación:
Año de incio:
2020
Año de finalización:
2023
ENSAYO CLÍNICO

Documentos

  • No hay documentos

Participantes

Grupos

Financiadores - Promotores

CELGENE CORPORATION

Resultados del Ensayo Clínico

[Translated article] Cybersecurity: a priority for pharmacy services in the age of artificial intelligence

Marin, Cayetano M. Hernandez, Monte-Boquet, Emilio, Andres, Jose Luis Poveda

Editorial Material. 10.1016/j.farma.2024.08.009. 2024

  • Open Access.

[Translated article] Good humanisation practices in the healthcare of patients with rare diseases in Pharmacy Services

Company Albir MJ, Andrés JLP, Solsona MDE

Article. 10.1016/j.farma.2023.10.004. 2024


[Translated article] New challenges in advanced therapies.

Megías-Vericat JE; (...); Poveda Andrés JL

Article. 10.1016/j.farma.2024.05.001. 2024


[Translated article] Pharmacokinetic-guided switching from standard half-life factor VIII to extended half-life pegylated factor VIII in haemophilia A therapy in clinical practice.

Chovi-Trull, Maria; (...); Andres, Jose Luis Poveda

Article. 10.1016/j.farma.2024.12.007. 2025


[Translated article] Real-world effectiveness and safety of nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma.

Fernandez, Laura Lorente; (...); Andres, Jose Luis Poveda

Article. 10.1016/j.farma.2024.09.006. 2024

  • Open Access.

2019 SEFH National Survey: service portfolio, care activities, education and research in Spain's hospital pharmacy departments.

Pérez-Encinas M; (...); Calleja-Hernández MÁ

Article. 10.7399/fh.11611. 2021


A multicriteria decision analysis (MCDA) applied to three long-term prophylactic treatments for hereditary angioedema in Spain

Zozaya, Neboa; (...); Hidalgo-Vega, Alvaro

Article. 10.33393/grhta.2022.2333. 2022


A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases.

Zozaya, Neboa; (...); Verde, Luis

Article. 10.1017/S0266462322000459. 2022


A phase Ib study of CC-90011, a potent, reversible, oral LSD1 inhibitor, plus etoposide and cisplatin (EP) or carboplatin (EC) in patients (Pts) with first-line (1L) extensive-stage (ES) small cell lung cancer (SCLC): Updated results

Ponce Aix, S.; (...); Paz-Ares, L.

Meeting Abstract. 2021


A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib.

Camidge DR; (...); Smit E

Article. 10.1016/j.cllc.2022.03.003. 2022


Alveolar capillary dysplasia with misalignment of the pulmonary veins: A surgical lung biopsy and autopsy in a full-term newborn.

Rodríguez García C; (...); Mancheño Franch N

Article. 10.1016/j.patol.2024.06.005. 2024


Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.

Passaro, A; (...); Cho, B C

Article. 10.1016/j.annonc.2023.10.117. 2024


An open-label, multicenter, phase 2 study of the safety and efficacy of navtemadlin (KRT-232) in patients with TP53 wild-type relapsed/refractory small cell lung cancer.

Dowlati, Afshin; (...); Carpeno, Javier de Castro

Meeting Abstract. 2022


Analysis of chemical contamination by hazardous drugs with BD HD Check(R) system in a tertiary hospital

Valero García S; (...); Poveda Andrés JL

Article. 10.1177/10781552211038518. 2021


Are there differences by sex in lung cancer characteristics at diagnosis? -a nationwide study.

Ruano-Ravina A; (...); Oramas J

Article. 10.21037/tlcr-21-559. 2021


Assessing the value of moderate-to-severe atopic dermatitis treatment using multi-criteria decision analysis (MCDA).

Pereyra-Rodríguez JJ; (...); Ortiz de Frutos FJ

Letter. 10.1111/jdv.19432. 2023


Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC.

Andric, Zoran; (...); Ciardiello, Fortunato

Article. 10.1016/j.jtocrr.2022.100461. 2023


Baricitinib against severe COVID-19: effectiveness and safety in hospitalised pretreated patients.

Iglesias Gómez R; (...); Poveda Andrés JL

Article. 10.1136/ejhpharm-2021-002741. 2021


Baseline circulating myeloid-derived suppressor cells correlate with neutrophil-to-lymphocyte ratio and overall survival in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors

Garcia-Sanchez, J.; (...); Lahoz, A.

Meeting Abstract. 2021


Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study.

Fernandez Rivera C; (...); Hernandez D

Article. 10.1111/ctr.14550. 2022


Capmatinib vs docetaxel as second- or third-line (2/3L) therapy in patients (pts) with METex14-mutated advanced NSCLC (aNSCLC): The GeoMETry-III trial

Vidal, O. J. Juan; (...); Wolf, J.

Meeting Abstract. 10.1016/j.annonc.2023.09.2424. 2023


Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients

Megias-Vericat, JE; (...); Poveda, JL

Article. 10.1016/j.thromres.2021.07.009. 2021


Clinical characteristics and survival in stage I-IIIA lung cancer resected patients in Spain, analyzed in the Thoracic Tumors Registry (TTR)

Franco, FF; (...); Provencio, M

Meeting Abstract. 10.1016/j.annonc.2021.08.1771. 2021


Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing: Results of the RING observational trial.

Romero A; (...); Provencio M

Article. 10.1002/1878-0261.12832. 2020


Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.

Montoro-Ronsano JB; (...); Soto-Ortega I

Article. 10.1016/j.farma.2023.01.003. 2023


Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.

Montoro-Ronsano, Jose Bruno; (...); Soto-Ortega, Inmaculada

Article. 10.1016/j.farma.2023.04.002. 2023


Correction to: SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022).

García-Campelo R; (...); Dómine M

Correction. 10.1007/s12094-023-03290-7. 2023


Correction: Pardo-Sánchez et al. Increased Tumor Growth Rate and Mesenchymal Properties of NSCLC-Patient-Derived Xenograft Models during Serial Transplantation. Cancers 2021, 13 , 2980.

Pardo-Sanchez, Jose Miguel; (...); Farràs R

Article. 10.3390/cancers13194825. 2021


Corrigendum to 'First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update': [ESMO Open Volume 6, Issue 5, October 2021, 100273].

Reck, M.; (...); John, T.

Correction. 10.1016/j.esmoop.2021.100345. 2021


COST-EFFECTIVENESS ANALYSIS OF DIFELIKEFALIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE ASSOCIATED-PRURITUS IN SPAIN

Sanchez-Alvarez, Emilio E.; (...); Hernaez Colque, M.

Meeting Abstract. 2024


Costs of the management of hemophilia A with inhibitors in Spain

Bonanad, S; (...); Gonzalez-Dominguez, A

Article. 10.33393/grhta.2021.2234. 2021


Current treatment landscape for oligometastatic non-small cell lung cancer

Garde-Noguera, Javier; (...); Counago, Felipe

Article. 10.5306/wjco.v13.i6.485. 2022


Cybersecurity, a priority for pharmacy services in the age of artificial intelligence.

Hernández Marín CM, Monte-Boquet E, Poveda Andrés JL

Editorial Material. 10.1016/j.farma.2024.08.001. 2024


Characterization of patients with advanced non-small-cell lung cancer (NSCLC) harboring KRASG12C mutation and their associated direct healthcare costs in Spanish routine clinical practice (SILK study)

Aransay, N. Reguart; (...); Vila, A. Lloansi

Meeting Abstract. 10.1016/j.annonc.2023.09.2442. 2023


Chronological and Biological Age as a Response Factor to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer

Suay, G.; (...); Juan-Vidal, O.

Meeting Abstract. 2024


Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study.

Ahn, Myung-Ju; (...); Sands, Jacob

Article. 10.1200/JCO-24-01544. 2024


Datopotamab Deruxtecan Vs Docetaxel in Patients with Non-Small Cell Lung Cancer: Final Overall Survival from TROPION-Lung01

Sands, J.; (...); Ahn, M-J

Meeting Abstract. 2024


Description of the clinical characteristics and survival in patients with metastatic NSCLC in the Spanish population: An analysis of the thoracic tumours registry (RTT study)

Franco, F; (...); Pulla, MP

Meeting Abstract. 10.1016/j.annonc.2020.08.1694. 2020


Design and rationale for a real-world prospective, multicenter registry of myocardial revascularization failure and secondary revascularization: The REVASEC study.

Salinas P; (...); Escaned J

Article. 10.1016/j.carrev.2021.11.015. 2021


Determination of essential biomarkers in lung cancer: A real-world data study in Spain

Calvo de Juan, V.; (...); Provencio Pulla, M.

Meeting Abstract. 10.1016/j.annonc.2022.02.048. 2022


Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics

Provencio, Mariano; (...); Torrente, Maria

Article. 10.1186/s12885-022-09830-8. 2022


Determining value in the treatment of activated PI3Kdelta syndrome in Spain: a multicriteria decision analysis from the perspective of key stakeholders.

Abad, Maria Reyes; (...); Gil, Alicia

Article. 10.33393/grhta.2024.3041. 2024


Determining what represents value in the treatment of prurigo nodularis and its key unmet needs in Spain through Multi-Criteria Decision Analysis

Silvestre, Juan Francisco; (...); Serra-Baldrich, Esther

Article. 10.1002/jvc2.275. 2024


Development of a predictive model for early detection of lung cancer: SREAL-eLUNG study

Vidal, O. J. Juan; (...); Martinez, B. Valdivieso

Meeting Abstract. 2023


Development of severity and mortality prediction models for covid-19 patients at emergency department including the chest x-ray.

Calvillo-Batllés P; (...); Martí-Bonmatí L

Article. 10.1016/j.rxeng.2021.09.004. 2022


Durvalumab (D) plus tremelimumab (T) in platinum-refractory/resistant extensive-stage small cell lung cancer (ES-SCLC): Efficacy, safety and ctDNA dynamics from Arm A of the phase 2 BALTIC study

Reinmuth, Niels; (...); Bondarenko, Igor

Meeting Abstract. 2022


ECONOMIC BURDEN OF ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS HARBORING KRASG12C MUTATION IN SPAIN

Fernandez-Barcelo, C.; (...); Sampietro-Colom, L.

Meeting Abstract. 2023


ECONOMIC IMPACT OF THE NSCLC MOLECULAR DIAGNOSIS IN SPAIN: A RETROSPECTIVE ANALYSIS OF HEALTHCARE RESOURCES USE AND ASSOCIATED COSTS FROM THE LUNG-ONE STUDY

de Castro, J; (...); Rojo, F

Meeting Abstract. 2020


Effectiveness of Caplacizumab Nanobody in Acquired Thrombotic Thrombocytopenic Purpura Refractory to Conventional Treatment

Palanques-Pastor T; (...); Poveda Andrés JL

Article. 10.1159/000517813. 2021


Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in non-small-cell lung cancer (NSCLC) with c-METexon 14 skipping mutations (METex14).

Brandao, Mariana da Rocha Almeida; (...); Felip, Enriqueta

Meeting Abstract. 2024

  • Open Access.

Endothelin-1-Mediated Drug Resistance in EGFR-Mutant Non-Small Cell Lung Carcinoma

Pulido, I; (...); Shimamura, T

Article. 10.1158/0008-5472.CAN-20-0141. 2020


Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry

Franco, F; (...); Provencio, M

Article. 10.1371/journal.pone.0251761. 2021


European Society of Medical Oncology (ESMO) guidelines for oncogene-addicted metastatic non-small cell lung cancer (NSCLC): a personalized treatment for each patient.

Suay, Guillermo, Aparisi, Francisco, Juan-Vidal, Oscar

Article. 10.21037/cco-23-100. 2024


Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer.

Arriola E; (...); Felip E

Article. 10.1007/s40261-024-01379-7. 2024


Extended follow-up of DURVAST trial: A phase II study evaluating durvalumab treatment in HIV-1-infected patients with solid tumours by the Spanish lung cancer group

Cao, MG; (...); Costa, RR

Meeting Abstract. 10.1016/j.annonc.2020.08.1589. 2020


Extensive stage (ES) small-cell lung cancer (SCLC) in Spain: A review of demographic, epidemiological and clinical data from the Thoracic Tumors Registry (TTR study)

Calvo, V; (...); Pulla, MP

Meeting Abstract. 10.1016/j.annonc.2020.08.1555. 2020


FAMetA: a mass isotopologue-based tool for the comprehensive analysis of fatty acid metabolism.

Alcoriza-Balaguer MI; (...); Lahoz A

Article. 10.1093/bib/bbad064. 2023


Family History of Cancer and Lung Cancer: Information from the Thoracic Tumors Registry (TTR Study)

Calvo, V.; (...); Provencio, M.

Meeting Abstract. 2021


Fetal exposure to tofacitinib during the first trimester: A healthy newborn case report

Fernandez-Sanchez, M; (...); Poveda-Andres, JL

Article. 10.1002/bdr2.1942. 2021


First-line (1L) nivolumab (N) plus ipilimumab (I) plus chemotherapy (C) vs C alone in patients (pts) with metastatic NSCLC (mNSCLC) from CheckMate 9LA: 4-y clinical update and outcomes by tumor histologic subtype (THS)

Carbone, David Paul; (...); Reck, Martin

Meeting Abstract. 2023


First-line (1L) nivolumab (N) plus ipilimumab (I) plus chemotherapy (C) vs C alone in patients (pts) with metastatic NSCLC (mNSCLC) from CheckMate 9LA: 4-y clinical update and outcomes by tumor histologic subtype (THS).

Carbone, David Paul; (...); Reck, Martin

Meeting Abstract. 10.1200/JCO.2023.41.17_suppl.LBA9023. 2023


First-line avelumab in combination with cetuximab and chemotherapy in patients with advanced squamous non-small cell lung cancer (NSCLC)

Andric, Z. G.; (...); Ciardiello, F.

Meeting Abstract. 2021


First-line Nivolumab (N) plus Ipilimumab (I) plus Chemotherapy (C) in Metastatic NSCLC (mNSCLC): CheckMate 9LA 4-Year Clinical Update

Baclin, Firas; (...); Reck, Martin

Meeting Abstract. 2024


First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA.

Reck, Martin; (...); John, Tom

Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.9000. 2021


First-line nivolumab (NIVO) plus ipilimumab (IPI)+2 cycles chemotherapy (chemo) vs 4 cycles chemo in advanced non-small cell lung cancer (aNSCLC): Association of blood and tissue tumor mutational burden (TMB) with efficacy in CheckMate 9LA

Paz-Ares, L.; (...); Carbone, D. P.

Meeting Abstract. 2021


First-line nivolumab (NIVO) plus ipilimumab (IPI)+2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): 2-year update from CheckMate 9LA

Reinmuth, N.; (...); John, T.

Meeting Abstract. 2021


First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.

Paz-Ares, Luis; (...); Reck, Martin

Article. 10.1016/S1470-2045(20)30641-0. 2021


First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817.

Ready, Neal E.; (...); Paz-Ares, Luis

Article. 10.1136/jitc-2022-006127. 2023


First-line Nivolumab plus Ipilimumab plus Chemo in Patients With Advanced NSCLC and Brain Metastases: Results From CheckMate 9LA

Carbone, D.; (...); Lu, S.

Meeting Abstract. 2021


First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations

Paz-Ares, Luis G.; (...); Carbone, David P.

Article. 10.1016/j.jtho.2022.10.014. 2023


First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update.

Reck M; (...); John T

Article. 10.1016/j.esmoop.2021.100273. 2021


First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes.

Reck, Martin; (...); Carbone, David P.

Article. 10.1016/j.ejca.2023.01.015. 2023


Five-year outcomes with first-line (1L) nivolumab plus ipilimumab plus chemotherapy (N plus I plus C) vs C in patients (pts) with metastatic NSCLC (mNSCLC) in CheckMate 9LA.

Reck, Martin; (...); Paz-Ares, Luis G.

Meeting Abstract. https://doi.org/10.1200/JCO.2024.42.16_suppl.8560. 2024


Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial.

Reck M; (...); Paz-Ares LG

Article. 10.1016/j.ejca.2024.114296. 2024


Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial.

Carbone DP; (...); Reck M

Article. 10.1136/jitc-2023-008189. 2024


FURTHER: A global study to evaluate furmonertinib in patients with EGFR mutant NSCLC including uncommon EGFR mutations (FURMO-002)

Le, Xiuning; (...); Wang, Jie

Meeting Abstract. https://doi.org/10.1200/JCO.2024.42.16_suppl.TPS8666. 2024

  • Open Access.

FURTHER: A Global, Randomized Study of Firmonertinib at Two Dose Levels in TKI-Naive, Advanced NSCLC with EGFR PACC Mutations

Le, X.; (...); Wang, J.

Meeting Abstract. 2024


GALLANT-1: Galectin-3 (Gal-3) inhibitor GB1211 plus atezolizumab (atezo) in patients with non-small cell lung cancer (NSCLC)-A randomized, double-blind trial.

Ghiringhelli, Francois; (...); Basse, Linda

Meeting Abstract. 2022


GALLANT-1: GB1211 galectin-3 (Gal-3) inhibitor plus atezolizumab (atz) for first line treatment in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC)

Aparisi Aparisi, F. D. A.; (...); Ghiringhelli, F.

Meeting Abstract. 10.1016/j.annonc.2023.09.2491. 2023


Genetic Variants Associated with Biological Treatment Response in Inflammatory Bowel Disease: A Systematic Review.

Plaza J; (...); Moret-Tatay I

Article. 10.3390/ijms25073717. 2024


Genotypic Characteristics and Resistance Mutations in Advanced ALK plus NSCLC: The ALK-PATHFINDER Study

Lopez Castro, R.; (...); Ponce Aix, S.

Meeting Abstract. 2023


Guide to Good Humanization Practices in Patients with Rare Diseases. who vadis

Poveda Andres, Jose Luis

Editorial Material. 2022


Healthcare Resource Utilization among Patients between 60-75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study

Solana-Altabella, Antonio; (...); Martinez-Cuadron, David

Article. 10.3390/cancers14081921. 2022


Health-Related Quality of Life (HRQoL) Outcomes with Adagrasib vs Docetaxel in KRASG12C-Mutated Advanced NSCLC in KRYSTAL-12

Felip, E.; (...); Duruisseaux, M.

Meeting Abstract. https://doi.org/10.1016/j.jtho.2024.09.056. 2024


High incidence of pulmonary thromboembolism in hospitalized SARS-CoV-2 infected patients despite thrombo-prophylaxis.

El-Qutob D; (...); Carrera-Hueso FJ

Article. 10.1016/j.hrtlng.2022.02.003. 2022


High risk of thrombosis in patients with advanced lung cancer harboring rearrangements in ROS1.

Muñoz-Unceta N; (...); Grupo de trombosis y cáncer SEOM

Article. 10.1016/j.ejca.2020.10.002. 2020


Hospital pharmacy initiatives for improving the management of patients with congenital coagulopathies

Bruno Montoro-Ronsano, Jose; (...); Alberto Vella, Vincenzo

Article. 10.7399/fh.11729. 2022


Hospitalization budget impact during the COVID-19 pandemic in Spain.

Carrera-Hueso, F. J.; (...); Crespo-Palomo, C.

Article. 10.1186/s13561-021-00340-0. 2021


How can artificial intelligence optimize value-based contracting?

Poveda, Jose Luis; (...); Medrano, Ignacio H.

Letter. 10.1186/s40545-022-00475-3. 2022


Immune checkpoint inhibitors as first-line treatment for brain metastases in stage IV NSCLC patients without driver mutations

Suay, Guillermo; (...); Lahoz, Agustin

Review. 10.1016/j.canlet.2024.217317. 2024


Immunogenicity of COVID-19 vaccines in lung cancer patients.

Provencio M; (...); Calvo V

Article. 10.1016/j.lungcan.2023.107323. 2023


Immunotherapy, chemotherapy and stereotactic radiotherapy to metastases, followed by definitive surgery or radiotherapy to the primary tumour, in patients with synchronous oligo-metastatic NSCLC: The ETOP CHESS trial

Guckenberger, M; (...); Stahel, RA

Meeting Abstract. 10.1016/j.annonc.2020.08.1731. 2020


Impact of Molecular Testing Using Next-Generation Sequencing in the Clinical Management of Patients with Non-Small Cell Lung Cancer in a Public Healthcare Hospital.

Simarro, Javier; (...); Palanca, Sarai

Article. 10.3390/cancers15061705. 2023


Incidence, risk factors, and thrombotic load of pulmonary embolism in patients hospitalized for COVID-19 infection.

García-Ortega A; (...); Martínez-García MÁ

Article. 10.1016/j.jinf.2021.01.003. 2021


Increased Tumor Growth Rate and Mesenchymal Properties of NSCLC-Patient-Derived Xenograft Models during Serial Transplantation

Pardo-Sanchez, JM; (...); Farras, R

Article. 10.3390/cancers13122980. 2021


Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia.

Megías-Vericat JE; (...); Montesinos P

Article. 10.1097/FPC.0000000000000431. 2021


Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis.

Pozo-Rosich P; (...); Irimia P

Article. 10.1186/s10194-024-01747-w. 2024


Isavuconazole Pharmacokinetics in Critically Ill Patients: Relationship with Clinical Effectiveness and Patient Safety.

Martin-Cerezuela, Maria; (...); Ramirez Galleymore, Paula

Article. 10.3390/antibiotics13080706. 2024


KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation

Mok, Tony S. K.; (...); Barlesi, Fabrice

Meeting Abstract. 10.1200/JCO.2024.42.17_suppl.LBA8509. 2024


Liposomal Irinotecan in Adults with Small Cell Lung Cancer who Progressed on Platinum-Based Therapy: Subgroup Analyses by Platinum Sensitivity

Spigel, DR; (...); Bunn, P

Meeting Abstract. 2021


Lung Cancer Symptoms at Diagnosis: Data from the Thoracic Tumors Registry (TTR Study).

Calvo, V; (...); Provencio, M

Meeting Abstract. 2021


Lung cancer symptoms at diagnosis: results of a nationwide registry study.

Ruano-Raviña A; (...); Cerezo S

Article. 10.1136/esmoopen-2020-001021. 2020


LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology

Garrido, P; (...); Felip, E

Article. 10.1002/cam4.4135. 2021


Management of flexible cavovarus foot in patients with Charcot-Marie-Tooth disease: midterm results.

Megías-Vericat JE; (...); Poveda-Andrés JL

Article. 2021

  • Open Access.

Manipulación de fármacos para su administración por gastrostomía endoscópica percutánea en pacientes con esclerosis lateral amiotrófica y nutrición enteral.

Vázquez Polo A; (...); Vázquez Costa JF

Article. 10.20960/nh.03946. 2022


Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A

Bonanad, S; (...); Santos, S

Article. 10.1007/s12325-021-01853-0. 2021


Metabolic Phenotyping in Prostate Cancer Using Multi-Omics Approaches.

Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor

Article. 10.3390/cancers14030596. 2022


Molecular diagnosis in non-small-cell lung cancer: expert opinion on ALK and ROS1 testing.

Conde E; (...); de Álava E

Article. 10.1136/jclinpath-2021-207490. 2021


Monitoring coagulation factors during surgery. A systematic review

Eduardo Megias-Vericat, Juan; (...); Luis Poveda-Andres, Jose

Review. 10.7399/fh.11766. 2021


Monitoring contamination of hazardous drug compounding surfaces at hospital pharmacy departments. A consensus Statement. Practice guidelines of the Spanish Society of Hospital Pharmacists (SEFH).

Valero-García S; (...); Delgado-Sánchez O

Article. 10.7399/fh.11655. 2021


Multi-Omic Approaches to Breast Cancer Metabolic Phenotyping: Applications in Diagnosis, Prognosis, and the Development of Novel Treatments

Gomez-Cebrian, N; (...); Pineda-Lucena, A

Review. 10.3390/cancers13184544. 2021


nab -Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+).

Morgensztern D; (...); Ong TJ

Article. 10.3389/fonc.2020.569715. 2021


Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non-Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial.

Spigel DR; (...); ABOUND.sqm Investigators

Article. 10.1016/j.cllc.2020.09.007. 2021


National Survey of the SEFH-2019: portfolio of services, healthcare activity, teaching and research in Hospital Pharmacy Services in Spain (vol 45, pg 32, 2021)

Perez-Encinas, Montserrat; (...); Angel Calleja-Hernandez, Miguel

Correction. 10.7399/fh.11740. 2021


National Survey on the Use of Mobile Applications in Patients with Hemophilia and Other Coagulopathies

Eduardo Megias, Juan; (...); Poveda Andres, Jose Luis

Meeting Abstract. 10.1182/blood-2022-169938. 2022


New challenges of advanced therapies.

Megías-Vericat JE; (...); Poveda Andrés JL

Article. 10.1016/j.farma.2023.11.008. 2024


NIVIPI-BRAIN, A Phase II Study of Nivolumab plus Ipilimumab Combined with Chemotherapy for Patients with NSCLC and Synchronous Brain Metastases

Nadal, E.; (...); Bruna, J.

Meeting Abstract. 2022


Nivolumab (NIVO) plus ipilimumab (IPI)+2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA

Reck, M; (...); Paz-Ares, LG

Meeting Abstract. 2020


Nivolumab (NIVO) plus ipilimumab (IPI)+2 Cycles of Platinum-Doublet Chemotherapy (Chemo) vs. 4 Cycles Chemo as First-Line (1L) Treatment) for Stage IV/Recurrent Non-Small Cell Lung Cancer (NSCLC): CheckMate 9LA

Reck, M; (...); Paz-Ares, LG

Meeting Abstract. 2021


Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small-Cell Lung Cancer: The Phase II BALTIC Study.

Reinmuth, Niels; (...); Bondarenko, Igor

Article. 10.1158/1078-0432.CCR-24-0013. 2024


Observational study to evaluate discontinuation of monotherapy with cobicistat-boosted darunavir in patients with human immunodeficiency virus

Solana-Altabella, Antonio; (...); Poveda-Andres, Jose Luis

Article. 10.1097/MD.0000000000032208. 2022


ODs with a positive TPR conclusion, not subject to a conditional approval, and approved without requering a pass would be more likely to be reimbursed in Spain.

Poveda JL; (...); Badia X

Article. 10.1186/s13023-022-02610-4. 2023


Omics-Based Approaches for the Characterization of Pompe Disease Metabolic Phenotypes

Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor

Review. 10.3390/biology12091159. 2023


OPTIMIZING MANAGEMENT AND OUTCOMES OF ACTIVATED PHOSPHOINOSITIDE 3-KINASE DELTA SYNDROME (APDS) IN SPAIN: BEWAYAPDS PROJECT

Flores-Moreno, S.; (...); Gil, A.

Meeting Abstract. 2024


Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group.

Provencio M; (...); Calvo V

Article. 10.1186/s12885-021-07922-5. 2021


OsimertinibTreatment in Non-Small Cell Lung Cancer (NSCLC) EGFR-T790M+. Activity in Patients with CNS Metastases. OSIREX

Terrasa, J; (...); Provencio, M

Meeting Abstract. 2021


Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol (vol 8, 372, 2020)

Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta

Correction. 10.3389/fped.2021.834454. 2022


Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project

Morillo-Verdugo, R; (...); Diaz-Olmo, J

Article. 10.7399/fh.11719. 2021


Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project.

Morillo-Verdugo R; (...); Díaz-Olmo J

Article. 2021

  • Open Access.

PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients.

Remon J; (...); Besse B

Article. 10.1016/j.cllc.2021.07.008. 2021


Pembrolizumab re-challenge in patients with relapsed non-small cell lung cancer (NSCLC): A preliminary report of the REPLAY phase II trial - cohort I

Ponce Aix, S.; (...); Paz-Ares, L.

Meeting Abstract. 10.1016/j.annonc.2021.10.179. 2021


Pharmacogenetics in Response to Biological Agents in Inflammatory Bowel Disease: A Systematic Review.

Ballesta-Lopez, Octavio; (...); Poveda-Andres, Jose Luis

Article. 10.3390/ijms26041760. 2025

  • Open Access.

Pharmacometabolomics by NMR in Oncology: A Systematic Review.

Gómez-Cebrián N; (...); Pineda-Lucena A

Article. 10.3390/ph14101015. 2021


Pharmacotherapeutic management of advanced therapy medicinal products

Luis Poveda-Andres, Jose; (...); Valero-Garcia, Silvia

Article. 10.7399/fh.13036. 2022


Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05).

Nadal E; (...); Bruna J

Article. 10.1200/JCO.22.02561. 2023


Plain language summary: tarlatamab for patients with previously treated small cell lung cancer.

Ahn, Myung-Ju; (...); Paz-Ares, Luis

Article. 10.1080/14796694.2024.2402152. 2024


Preliminary results from PROPEL: A phase I/II study of bempegaldesleukin (BEMPEG: NKTR-214) plus pembrolizumab (PEMBRO) with or without chemotherapy in patients with metastatic NSCLC

Felip, E.; (...); Ganti, A.

Meeting Abstract. 10.1016/j.annonc.2021.10.159. 2021


Preparation and administration of insulin infusions in neonatology: A national survey.

Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta

Article. 10.1016/j.anpede.2020.06.015. 2021


Presence of good humanization practices in the healthcare of patients with rare diseases in Pharmacy Services

Company Albir MJ, Poveda Andrés JL, Edo Solsona MD

Article. 10.1016/j.farma.2023.06.0131130. 2024

  • Open Access.

Proactive therapeutic drug monitoring and pharmacogenetic analysis in inflammatory bowel disease: A systematic review

Ballesta-Lopez, Octavio; (...); Luis Poveda-Andres, Jose

Review. 10.7399/fh.11780. 2021


Profile of Comorbidities and Cancer History in Patients with mNSCLC in the Spanish Population (Thoracic Tumors Registry).

Franco, F; (...); Provencio, M

Meeting Abstract. 2021


Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data

Gutierrez, L; (...); Provencio, M

Article. 10.1186/s12885-021-08713-8. 2021


PROPEL: A Phase 1/2 Trial of Bempegaldesleukin (NKTR-214) Plus Pembrolizumab in Lung Cancer and other Advanced Solid Tumors

Spigel, DR; (...); Reck, M

Meeting Abstract. 2021


Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study

Jantus-Lewintre, E; (...); Grp Espanol Canc Pulmon GECP

Article. 10.3389/fonc.2021.695038. 2021


Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer.

Edelman, Martin J.; (...); DISTINCT Study Investigators

Article. 10.1016/j.lungcan.2022.03.003. 2022


Real-world outcomes of first-line pembrolizumab (Pem) for metastatic non-small cell lung cancer (mNSCLC) with >= 50% expression of programmed cell death-ligand 1 (PD-L1): A multicentre retrospective study

Perea, J.; (...); Gaudens, P. Capdevila

Meeting Abstract. 2023


RESILIENT part 1: A phase 2 dose-exploration and dose-expansion study of second-line liposomal irinotecan in adults with small cell lung cancer.

Paz-Ares, Luis; (...); Bunn, Paul A.

Article. 10.1002/cncr.34123. 2022


RESILIENT part 1: Pharmacokinetics of second-line (2L) liposomal irinotecan in patients with small cell lung cancer (SCLC)

Ponce, S; (...); Bunn, PA

Meeting Abstract. 10.1016/j.annonc.2020.08.1554. 2020


RESILIENT Part 1: Safety and Efficacy of Second-Line Liposomal Irinotecan in Patients with Small Cell Lung Cancer

Paz-Ares, L; (...); Bunn, P

Meeting Abstract. 2021


RESILIENT Part 2: A phase 3 Study of Liposomal Irinotecan in Patients with Small-Cell Lung Cancer in the Second-Line Setting

Paz-Ares, L; (...); Bunn, P

Meeting Abstract. 2021


RET Fusion Testing in Advanced Non-Small Cell Lung Carcinoma Patients: the RETING Study

Conde, E.; (...); Lopez-Rios, F.

Meeting Abstract. 2021


RET Fusion Testing in Patients With NSCLC: The RETING Study.

Conde, Esther; (...); Lopez-Rios, Fernando

Article. 10.1016/j.jtocrr.2024.100653. 2024


RET Fusion Testing with FISH and Real-Time PCR: a Comparison with RNA-Based Next-Generation Sequencing in RET Positive NSCLC

Hernandez, S.; (...); Conde, E.

Meeting Abstract. 2022


Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1inhibitors (IO): Primary results from the phase 3 EVOKE-01 study.

Paz-Ares, Luis G.; (...); Garassino, Marina Chiara

Meeting Abstract. 10.1200/JCO.2024.42.17_suppl.LBA8500. 2024


Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study.

Paz-Ares, Luis G.; (...); Garassino, Marina Chiara

Article. 10.1200/JCO.24.00733. 2024


Sacituzumab Govitecan vs Docetaxel in Patients with mNSCLC Non-responsive to Last Anti-PD-(L)1containing Regimen: EVOKE-01

Garassino, M. C.; (...); Paz-Ares, L. G.

Meeting Abstract. 2024

  • Open Access.

Second-Line Nivolumab in Relapsed Small-Cell Lung Cancer: CheckMate 331.

Spigel DR; (...); Reck M

Article. 10.1016/j.annonc.2021.01.071. 2021


Second-line treatment in advanced non-squamous (NS) non-small cell lung cancer (NSCLC) patients in Spain, analyzed in the Thoracic Tumor Registry (RTT)

Carcereny Costa, E.; (...); Provencio Pulla, M.

Meeting Abstract. 10.1016/j.annonc.2022.02.062. 2022


SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022).

Garcia-Campelo, Rosario; (...); Domine, Manuel

Article. 10.1007/s12094-023-03216-3. 2023


Sequential chemotherapy regimen of induction with panitumumab and paclitaxel followed by radiotherapy and panitumumab in patients with locally advanced head and neck cancer unfit for platinum derivatives. The phase II, PANTERA/TTCC-2010-06 study.

Martínez-Trufero J; (...); Mesía Nin R

Article. 10.1007/s12094-021-02567-z. 2021


Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients (p): SOLID study.

Provencio, Mariano; (...); Cobo, Manuel

Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.8531. 2021


Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study.

Provencio, Mariano; (...); Cobo, Manuel

Article. 10.21037/tlcr-21-504. 2022


Sex differences in the diagnosis, treatment and prognosis of cancer: the rationale for an individualised approach.

Vera, Ruth; (...); del Alba, Aranzazu Gonzalez

Article. 10.1007/s12094-023-03112-w. 2023


Sex Differences in the Efficacy of Immune Checkpoint Inhibitors in Neoadjuvant Therapy of Non-Small Cell Lung Cancer: A Meta-Analysis

Suay, Guillermo; (...); Juan-Vidal, Oscar

Review. 10.3390/cancers15184433. 2023


Small cell lung cancer (SCLC) extensive stage (ES) in Spain: Efficacy of treatments, data from the thoracic tumours registry (TTR study)

Carcereny Costa, E.; (...); Provencio Pulla, M.

Meeting Abstract. 10.1016/j.annonc.2020.08.1547. 2020

  • Open Access.

SMPTall man lettering application in medication information systems as a quality and safety strategy in hospital organization

Iglesias Gomez, Ruben; (...); Poveda Andres, Jose Luis

Article. 10.1111/jcpt.13703. 2022


Spanish cardiac catheterization and coronary intervention registry. 32nd official report of the Interventional Cardiology Association of the Spanish Society of Cardiology (1990-2022).

Jurado-Román A; (...); García de la Borbolla Fernández R

Article. 10.1016/j.rec.2023.07.012. 2023


Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer.

Peressini M; (...); Zugazagoitia J

Article. 10.1158/1078-0432.CCR-24-0104. 2024


Stereotactic body radiation therapy: A good dance partner of oligometastatic non-small cell lung cancer to the sound of SINDAS study.

Mielgo-Rubio X; (...); Couñago F

Editorial Material. 10.5306/wjco.v11.i12.983. 2020


Survival outcomes in ALK-positive NSCLC patients (p) treated 1st line brigatinib and impact of the ALK fusion variant

Provencio-Pulla, Mariano; (...); Romero, Atocha

Meeting Abstract. 2023


Survival, quality of life (QoL) and geriatric outcomes of elderly patients (pt) with advanced non-small cell lung cancer (NSCLC), treated with pembrolizumab (P) in the first-line setting

Blanco, R; (...); Vidal, OJJ

Meeting Abstract. 10.1016/j.annonc.2020.08.1631. 2020


Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia

Megías-Vericat JE; (...); Montesinos P

Review. 10.3390/pharmaceutics14040878. 2022


Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer.

Ahn MJ; (...); Paz-Ares L

Article. 10.1056/NEJMoa2307980. 2023


Technical Validation and Clinical Implications of Ultrasensitive PCR Approaches for EGFR-Thr790Met Mutation Detection in Pretreatment FFPE Samples and in Liquid Biopsies from Non-Small Cell Lung Cancer Patients

Simarro, Javier; (...); Palanca, Sarai

Article. 10.3390/ijms23158526. 2022


The association of salivary caffeine levels with serum concentrations in premature infants with apnea of prematurity

Garcia-Robles, Ana; (...); Saenz Gonzalez, Pilar

Article. 10.1007/s00431-022-04628-z. 2022


The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis.

Gil-Nagel A; (...); Gil A

Article. 10.1016/j.yebeh.2022.108711. 2022


The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy.

Gomez Rueda, Ana; (...); Garrido, Pilar

Article. 10.1007/s12094-024-03404-9. 2024


The value of the reflective discussion in decision-making using multi-criteria decision analysis (MCDA): an example of determining the value contribution of tabelecleucel for the treatment of the Epstein Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD).

Badia, Xavier; (...); Valles, Joan-Antoni

Article. 10.1186/s13023-024-03324-5. 2024

  • Open Access.

Thoracic Tumors Registry (RTT): Analysis of Clinical Features and Survival in Patients with mNSCLC in Spain.

Franco, F; (...); Provencio, M

Meeting Abstract. 2021


Toxic-metabolic encephalopathy induced by metronidazole and disulfiram: classics never die.

Chovi-Trull, Maria; (...); Poveda-Andres, Jose Luis

Article. 10.1136/ejhpharm-2024-004184. 2024


Transcriptomic analysis of pre-treatment tissue samples to predict clinical benefit to durvalumab in HIV-infected cancer patients

Wilhelmina Bracht, Jillian; (...); Rosell, Rafael

Meeting Abstract. 10.1158/1538-7445.AM2020-929. 2020


Translation of a tissue epigenetic signature to circulating free DNA suggests BCAT1 as a potential noninvasive diagnostic biomarker for lung cancer

Palanca-Ballester, Cora; (...); Sandoval, Juan

Article. 10.1186/s13148-022-01334-3. 2022


Treatment strategy optimization for patients with non-small-cell lung cancer harboring EGFR mutation: a Delphi consensus.

Isla D; (...); Juan-Vidal O

Article. 10.1007/s12094-020-02518-0. 2021


Updated analysis from the ATEZO-BRAIN trial: Atezolizumab plus carboplatin and pemetrexed in patients with advanced nonsquamous non-small cell lung cancer with untreated brain metastases.

Nadal, Ernest; (...); Bruna, Jordi

Meeting Abstract. 2022


Utility of Next-Generation Sequencing in the Reconstruction of Clonal Architecture in a Patient with an EGFR Mutated Advanced Non-Small Cell Lung Cancer: A Case Report.

Simarro J; (...); Palanca S

Article. 10.3390/diagnostics12051266. 2022


Utility of the Biomarker CA125 in the Diagnosis of Cellular Rejection in Allogeneic Heart Transplantation.

Lopez-Vilella, R; (...); Bonet, LA

Article. 10.1016/j.transproceed.2021.07.058. 2021


VALUE CRITERIA FOR OUTCOMES BASED MANAGED ENTRY AGREEMENT OF CAR-T IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) THROUGH MCDA

Poveda, J. L.; (...); Lizan, L.

Meeting Abstract. 2023


Campos de estudio

Compartir